Lv31
244 积分 2022-01-04 加入
Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties
1小时前
待确认
Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based SHP2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the Treatment of KRAS Mutant Cancers
30天前
已完结
Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery
1个月前
已完结
Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation Field
1个月前
已完结
The E3 ligase adapter cereblon targets the C-terminal cyclic imide degron
2个月前
已完结
Cyclic Peptides for Drug Development
2个月前
已完结
A new and rapid colorimetric determination of acetylcholinesterase activity
2个月前
已完结
Pyrrolysyl-tRNA synthetase–tRNAPyl structure reveals the molecular basis of orthogonality
2个月前
已完结
Methods for Quantitative Assessment of Protein Degradation
3个月前
已完结
Drug Synthesis and Analysis of an Acetylcholinesterase Inhibitor: A Comprehensive Medicinal Chemistry Experience for Undergraduates
4个月前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
4个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
4个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
4个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
4个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
4个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
4个月前
已采纳
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
4个月前
已采纳
皖公网安备34019202002308
